Genetic polymorphisms in Cytochrome P4501B1 and susceptibility to Head and Neck Cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 639, Issue 1-2, 2008, Pages 11-19

  Singh, Arvind P ^a   Shah, Parag P ^a   Mathur, Neeraj ^a   Buters, Jeroen T M ^b   Pant, Mohan C ^c   Parmar, Devendra ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Cytochrome P450; Haplotypes; Head and neck squamous cell carcinoma; Linkage disequilibrium; Single nucleotide polymorphisms

Indexed keywords

ALANINE; ALCOHOL; AMINO ACID; ANTINEOPLASTIC AGENT; ARGININE; ASPARAGINE; CYTOCHROME P450 1B1; GLYCINE; LEUCINE; SERINE; VALINE;

ARTICLE; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CODON; CONTROLLED STUDY; ENVIRONMENT; FEMALE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASTICATION; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TOBACCO;

ALCOHOL DRINKING; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, GENETIC; SMOKING; TOBACCO USE DISORDER;

NICOTIANA TABACUM;

EID: 39249084434     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.10.007     Document Type: Article

References (37)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 54 (1993) 594-606
2. Brennan P., and Boffetta P. Mechanistic considerations in the molecular epidemiology of head and neck cancer. IARC Sci. Publ. 157 (2004) 393-414
3. Hakim P.P. Head and neck cancer-the Indian scene. Int. Congress Ser. 1240 (2003) 973-984
4. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., and Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 3-28
5. Olshan A.F., Weissler M.C., Watson M.A., and Bell D.A. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 185-191
6. Sreelekha T.T., Ramadas K., Pandey M., Thomas G., Nalinakumari K.R., and Pillai M.R. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol. 37 (2001) 593-598
7. Shimada T., and Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 95 (2004) 1-6
8. Buters J., Quintanilla-Martinez L., Schober W., Soballa J.V., Hintermair J., Wolff T., Gonzalez F.J., and Greim H. CYP1B1 determine susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. Carcinogenesis 24 (2003) 327-334
9. Buters J.T., Mahadevan B., Quintanilla-Martinez L., Gonzalez F.J., Greim H., Baird M., and Luch A. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l] pyrene-induced tumor formation. Chem. Res. Toxicol. 15 (2002) 1127-1135
10. Murray G.I., Taylor M., Mc Fadyen M.C., McKay J.A., Greenlee W.F., Burke M.D., and Melvin W.T. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57 (1997) 3026-3031
11. Shimada T., Hayes C., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., and Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56 (1996) 2979-2984
12. Ko Y., Abel J., Harth V., Brode P., Antony C., Donat S., Fischer H.P., Ortiz-Pallardo M.E., Thier R., Sachinidis A., Vetter H., Bolt H.M., Herberhold C., and Bruning T. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res. 61 (2001) 4398-4404
13. Stoilov I., Akarsu A.N., Alozie I., Child A., Barsoum-Homsy M., Turacli M.E., Or M., Lewis R.A., Ozdemir N., Brice G., Aktan S.G., Chevrette L., Coca-Prados M., and Sarfarazi M. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. 62 (1998) 573-584
14. Aklillu E., Oscarson M., Hidestrand M., Leidvik B., Otter C., and Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol. Pharmacol. 63 (2002) 586-594
15. Roos P.H., and Bolt H.M. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin. Drug Metab. Toxicol. 2 (2005) 187-202
16. Shimada T., Watanabe J., Inoue K., Guengerich F.P., and Gillam E.M. Specificity of 17beta-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica 31 (2001) 163-176
17. Mammen J.S., Pittman G.S., Li Y., Abou-Zahr F., Bejjani B.A., Bell D.A., Strickland P.T., and Sutter T.R. Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 4 (2003) 1247-1255
18. Thier R., Bruning T., Roos P.H., and Bolt H.M. Cytochrome P450 1B1, a new keystone in gene-environment interactions related to human head and neck cancer?. Arch. Toxicol. 76 (2002) 249-256
19. Li G., Liu Z., Sturgis E.M., Chamberlain R.M., Spitz M.R., and Wei Q. CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1334-1336
20. Tang M.Y., Green L., Chen G.H., Thompson A.P., Lang P.N., Shinde A., Lin X.D., Tan W., Cook L.D.B., Hammons J.G., and Kadlubar F.F. Human CYP1B1 Leu432Val gene polymorphisms: ethnic distribution in Americans, Caucasian and Chinese, oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10 (2000) 761-766
21. Sutter H.C., Qian Z., Hong P.Y., Mammen S.J., Strickland T.P., and Thomas R. Genotyping human cytochrome: P450 1B1 variants vol. 357 (2002), Methods Enzymol Academic Press, United States pp. 53-58
22. Jaworowska E., Masojc B., Tarnowska C., Brzosko M., Flicinski J., Serrano-Fernandez P., Matyjasik J., Amernik K., Scott R.J., and Lubinski J. Association between early-onset breast and laryngeal cancers. Breast Cancer Res. Treat. 97 (2006) 215-219
23. Watanabe J., Shimada T., Gillam E.M., Ikuta T., Suemasu K., Higashi Y., Gotoh O., and Kawajiri K. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10 (2000) 25-33
24. Tanaka Y., Sasaki M., Kaneuchi M., Shiina H., Igawa M., and Dahiya R. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem. Biophys. Res. Commun. 296 (2002) 820-826
25. Sorensen M., Autrup H., Tjonneland A., Overvad K., and Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett. 221 (2005) 185-190
26. Landi M.T., Bergen A.W., Baccarelli A., Patterson Jr. D.G., Grassman J., Ter-Minassian M., Mocarelli P., Caporaso N., Masten S.A., Pesatori A.C., Pittman G.S., and Bell D.A. CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology 207 (2005) 191-202
27. Chakrabarti S., Kaur K., Kaur I., Mandal A.K., Parikh R.S., Thomas R., and Majumder P.P. Globally, CYP1B1 mutations in primary congenital glaucoma are strongly structured by geographic and haplotype backgrounds. Invest. Ophthalmol. Vis. Sci. 47 (2006) 43-47
28. Jansson I., Stoilov M., and Sarfarazi J.B. Schenkman Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolism. Pharmacogenetics 11 (2001) 793-801
29. Chang B.L., Zheng S., Isaacs S.D., Turner A., Hawkins G.A., Wiley K.E., Bleecker E.R., Walsh P.C., Meyers D.A., Isaacs W.B., and Xu J. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br. J. Cancer 89 (2003) 1524-1529
30. Chang B.L., Zheng S., Isaacs S.D., Turner A., Hawkins G.A., Wiley K.E., Bleecker E.R., Walsh P.C., Meyers D.A., Isaacs W.B., and Xu J. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int. J. Cancer 106 (2003) 375-378
31. Sasaki M., Tanaka Y., Kaneuchi M., Sakuragi N., and Dahiya R. Alleles of polymorphic sites that correspond to hyperactive variants of CYP1B1 protein are significantly less frequent in Japanese as compared to American and German populations. Hum. Mutat. 21 6 (2003) 652
32. IARC. Monograph on the Evaluation of the Carcinogenic Risk of Chemicals to Humans - Tobacco Smoking vol. 38 (1986), IARC Sci. Publ. pp. 1-3
33. Nair U., and Bartsch H. Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer. IARC Sci. Publ. 154 (2001) 271-290
34. Aklillu E., Ovrebo S., Botnen I.V., Otter C., and Ingelman-Sundberg M. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res. 65 (2005) 5105-5111
35. Hopfer C.J., Stallings M.C., and Hewitt J.K. Common genetic and environmental vulnerability for alcohol and tobacco use in a volunteer sample of older female twins. J. Stud. Alcohol 62 (2001) 717-723
36. IARC. Alcohol drinking. Biological data relevant to the evaluation of carcinogenic risk to humans. IARC Monogr. Eval. Carcinog. Risks Hum. 44 (1988) 101-152
37. Wight A.J., and Ogden G.R. Possible mechanisms by which alcohol may influence the development of oral cancer-a review. Oral Oncol. 34 6 (1998) 441-447